The UK and Singapore have launched a regulatory corridor to fast-track health tech, giving companies joint access to MHRA and HSA from 12 December.
A regulatory innovation corridor lets developers seek early, informal joint advice from two regulators to plan trials, avoid duplication and cut delays while maintaining safety standards.
Flagship Pioneering is the first partner. Focus areas include cancer, neurodegenerative disease, obesity, rare diseases and advanced diagnostics. Therapeutic modalities means types of treatment, such as genetic medicines and immunotherapies.
The partnership also ties into AI oversight. MHRA initiatives include the AI Airlock for medical devices, the Innovative Licensing and Access Pathway and Centres of Excellence for Regulatory Science and Innovation. HSA’s work includes ASCENT, a centre for next-generation therapeutics with A*STAR, and updated AI in Healthcare Guidelines published by the Ministry of Health, HSA and Synapxe.
Health innovation minister Dr Zubir Ahmed said: “This partnership is exactly the kind of innovation we need to deliver on our mission to build an NHS fit for the future. Working with Singapore to fast-track breakthrough treatments in areas like cancer, dementia and rare diseases means NHS patients could get faster access to life-changing therapies. By enabling companies to work with both regulators at once, we’re also making the UK more attractive for life sciences investment and securing the high-skilled jobs and research that comes with it. That’s good for patients and good for the economy.”
Science minister Lord Patrick Vallance said: “Singapore is renowned for its excellence in medical research and innovation, and already has strong ties with the UK. By working together, we can streamline regulatory processes and remove unnecessary barriers, making it easier for researchers to run clinical trials in both our countries. That means more investment, more cutting-edge research, and ultimately faster access to new medicines for patients, with the added benefit of ensuring the UK remains at the forefront of global health innovation.”
Lawrence Tallon, chief executive of the MHRA, said: “This new fast-track route marks a significant shift in how trusted regulators can work together. By bringing together the UK’s research strength with Singapore’s agile approach to emerging technologies and working early with companies like Flagship Pioneering, we can help companies build better evidence from the start and avoid delays in development. For patients in the UK, this means earlier access to promising treatments in areas where progress is urgently needed. Safety remains at the heart of our mission, and this partnership strengthens our ability to assess fast-moving science while maintaining the high standards the public expects. This approach also supports the wider UK life sciences economy. A clearer, more predictable path to market helps attract global investment, gives innovators confidence to develop their products here, and strengthens the UK’s position as a leading hub for the next generation of medicines and medical technologies.”
Adjunct Professor (Dr) Raymond Chua, chief executive of the Health Sciences Authority, said: “The Regulatory Innovation Corridor marks a significant milestone in how two regulators, Singapore’s HSA and the UK’s MHRA, can come together to advance global regulatory innovation and benefit patients. Building on our strong collaborative work through the Access Consortium, both HSA and MHRA will co-create transparent, science-based approaches to assess breakthrough technologies. And we are indeed glad to have Flagship Pioneering as the first company accessing this new corridor, which will foster shared learning between all parties, and future partners, to enable more forward-looking pathways to move breakthrough ideas in key priority areas from lab to market. This partnership advances our shared commitment to regulatory science and excellence, and to support Singapore’s latest research priorities, enabling faster, smarter pathways for innovation while maintaining public trust and patient safety.”
Noubar Afeyan, founder and chief executive at Flagship Pioneering, said: “Global challenges in human health demand global regulatory innovation. By establishing this corridor, the UK and Singapore are signalling a shared commitment to accelerating breakthrough science responsibly and at scale. Through this partnership, Flagship Pioneering and our companies can engage earlier and more efficiently with two highly respected regulators, helping us advance transformative technologies that have the potential to redefine patient care. We view this as a model for how forward-looking nations can work with innovators to unlock faster, safer paths to patient impact.”
